Who should not take SS-31 (Elamipretide / MTP-131)?
Documented caution flags for SS-31 (Elamipretide / MTP-131) include pregnancy / nursing and no data in active malignancy. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for SS-31 (Elamipretide / MTP-131) is limited.
Documented caution flags for SS-31 (Elamipretide / MTP-131)
- Pregnancy / nursing
- No data in active malignancy
Reported side effects to weigh
- Generally well tolerated
- Injection-site irritation
- Rare: headache
References
- Elamipretide in primary mitochondrial myopathy (MMPOWER trials) — Karaa A et al., Neurology, 2018
- Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER — Thompson WR, Manuel R, Abbruscato A, et al. — Genetics in Medicine, 2024
- FORZINITY (elamipretide hydrochloride) injection — FDA Prescribing Information — FDA / DailyMed (Stealth BioTherapeutics), 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on SS-31 (Elamipretide / MTP-131)
Full SS-31 (Elamipretide / MTP-131) breakdownSS-31 (Elamipretide / MTP-131) what it's used forSS-31 (Elamipretide / MTP-131) side effectsSS-31 (Elamipretide / MTP-131) how to take itSS-31 (Elamipretide / MTP-131) mistakes to avoidSS-31 (Elamipretide / MTP-131) half-lifeSS-31 (Elamipretide / MTP-131) how long to workSS-31 (Elamipretide / MTP-131) legal statusSS-31 (Elamipretide / MTP-131) how it worksAsk the AI Coach
Last updated 2026-06-15.